A Europe-based investment group invests through an evergreen structure. The firm typically deploys approximately $2–$20M per company and invests primarily in private companies with a focus on the Nordic region. Investments are generally structured as equity, although convertible loans may also be considered. The firm has a long track record of supporting healthcare companies through growth and public-market exits and typically seeks a small number of new investments each year.
Within life sciences and healthcare, the firm focuses on therapeutics, medical technology, and healthtech. For therapeutics, the firm generally targets clinical-stage drug development companies and has particular interest in oncology and orphan or rare diseases. Within medical technology, the firm considers all device classes but generally favors companies approaching commercialization. In healthtech, the firm prioritizes solutions with demonstrated willingness to pay and sustainable business models, with a particular preference for B2B opportunities.
From a company and management team perspective, the firm seeks private companies with strong development or commercial potential and takes an active approach following investment. The firm generally seeks board representation and works closely with portfolio companies as they progress through clinical development, commercialization, growth, and potential exit opportunities.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 